tag:blogger.com,1999:blog-8550428.post2455148122405330343..comments2024-03-27T01:34:23.434-04:00Comments on Pharma Marketing Blog: CEI's Critique of FDA's Paid Search Stance Should be Titled "The Little (Search) Engine that Could"Vladhttp://www.blogger.com/profile/04114063498108633047noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-8550428.post-5462302984849292112009-10-13T17:21:53.884-04:002009-10-13T17:21:53.884-04:00When the survey is finished and I submit it ti the...When the survey is finished and I submit it ti the FDA, I will include the sample size.PharmaGuyhttps://www.blogger.com/profile/10211557578124130640noreply@blogger.comtag:blogger.com,1999:blog-8550428.post-17128881680770048752009-10-13T17:14:17.286-04:002009-10-13T17:14:17.286-04:00John,
Are you kidding me? You chose one item of ...John,<br /><br />Are you kidding me? You chose one item of reasonable conjecture to write two articles on the CEI article? You dispute this one item of conjecture with your own conjecture and some equally anecdotal "testing." <br /><br />Its kind of pity that I don't understand what ax you have to grind sometimes, but its a disservice. In fact, your reporting, analysis or blogging (whatever you want to call it) ignores nearly the entire CEI article which is an excellent analysis of FDA's policy contradictions and clearly an excellent starting point for challenging FDA's policy based on its own precedents. The article also has a good analysis of how FDA's enforcement underestimates the cababilities of consumers to navigate the web (This coming from an agency that still makes companies submit all promotional materials to DDMAC on a paper form 2253 and won't accept electronic transmission even though the technology and most of the infrastructure has been in place for years. Don't get me started on FDA's continued reliance on FAX machines. This is then the same agency who judges consumer's technology capabilities through the telescope of its own technological deficiencies.)<br /><br />Whether or not the theory that sponsored link restrictions on prescription manufactures negatively alters the information eco system will only be evaluated by time. There are many factors that could occur in the future that could change those search results you created. Overgrowth can occur in the absence of another organism competing for a resource. That said, one solution would simply be to ensure the FTC actually regulates effectively dubious health marketing claims. Unfortunately, they'll be more like the orkin man trying to get rid of your stink bugs. A false or misleading ad is a false or misleading ad and there are instruments (and regulatory authorities and consumer protection mechanisms like the FTC) to wield these instuments. Except, at least today (and in my opinion) the FTC does a woeful job at enforcing against false and miseading advertising. <br /><br />Also, for one who has frequently portrayed FDA as inept half-witted in your blog, it is awfully ironic how senstitive you now are to the common FDA man/woman. Carelessly wrought BS indeed. Also, I'm pretty sure Arnie has some perspective on what its like to be inside FDA and getting policies challenged. So I'm pretty sure I can trust the validity of his approach, in spite of the inevitable holes. <br /><br />Nonetheless, I remain an avid reader because I know you'll post this. <br /><br />One last thing, when you post your survey results, can you post the sample size of the survey respondents? That's data transparency/reporting basics. Something DDMAC would cite you for failing to reveal material facts. Unless of course I'm missing something.John Murrayhttp://www.grayscalecompliance.comnoreply@blogger.com